After 1st part of Stage 2 of the phase 3, we will have the data to apply for accelerated approval from USA FDA.
TGA provisional approval might come around faster than June 2025 (they know us, well).
If we get DMOAD label clarity, 2x2 dose, a 30mill USD China deal (upfront) is low. We have other levers to pull on too.
MPS could surprise. MPS/OA, MPS/OA Aus…. OA China…. LATAM and Mena….
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-171
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $216.0K | 1.057M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 143324 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 44935 | 3 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |